The Allemand Bayer Pharmaceutical Group will pay 110 million dollars to make money on those 500 claims against their contraceptive pills Yasmin and Yaz. Ces demières seraient susceptibles d'entrainer la formation de caillots sanguins pouvant provoquer des infarctus et ce risqué n'aurait pas été suffisamment souligné. C'est en tout cas l'avis de la FDA qui a demandé le 10 avril dernier à Bayer et d'autres manufacturers de pilules contraceptives de le signaler plus clairement Avec 1,58 milliard de dollars de chiffre d'affaires, ces contraceptifs arrivent au deuxième rang dans la gamme de Bayer en termes de chiffre d'affaires. Bayer préfère avoid the risks and the cofits of a procès aux Etats-Unis.
Les Echos 16-04-2012
Translation:
The German pharmaceutical group Bayer will have to pay at least $110 million to settle about 500 claims against its Yasmin and Yaz contraceptives. The latter could favor the formation of clots that can cause heart attacks and this risk is not sufficiently highlighted. This is the opinion of the FDA which on April 10 asked Bayer and other manufacturers of contraceptive pills to report it more clearly. With 1.58 billion in sales, these contraceptives come in second place in Bayer's product range in terms of sales. Bayer prefers to avoid the risks and costs of an additional trial in the United States.
